Description

Parapox Ovis Virus Immunomodulator is used in the treatment of equine herpes virus types 1 and 4. Studies indicate that this vaccine is effective in establishing an immune response that reduces the severity and duration of these viral diseases.

The parapox ovis virus activates immune cells, stimulates phagocytosis and induces expression of cytokines; the messenger proteins that stimulate production of interferon and immune cells in a number of species. The immune cells and phagocytes target the EHV and reduces the damage caused by the virus and the duration of the illness.

Clinical studies show a reduction in the number of days and amount of nasal discharge in horses that are treated with the parapox ovis virus versus a control group.

Usage

A series of intramuscular injections of the parapox ovis virus immunomodulator is called for during disease episodes, or in periods of stress such as showing, trailering, breeding, or environmental changes that increase the likelihood of EHV disease in susceptible horses or foals above 4 months in age.

Dosage and Administration

Side Effects

ZYLEXIS has undergone testing in a field safety trial in the US in 333 horses of various breeds ranging in age from 4 months to 20 years. No adverse events were reported.

Precautions

Use entire contents when first opened. Sterilized syringes and needles should be used to administer this immunomodulator. Do not administer within 21 days before slaughter. In case of anaphylaxis, administer epinephrine or equivalent.

Interactions

None reported.

Overdose

No information is provided in the literature concerning accidental overdose of this vaccine. Contact the manufacturer directly for instructions should an overdose occur.